Literature DB >> 12242127

Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients.

Mehmet Koc1, Pinar Polat, Selami Suma.   

Abstract

BACKGROUND AND
PURPOSE: This study was performed to investigate whether the tamoxifen (TAM) induced the development of pulmonary fibrosis after post-mastectomy cobalt-60 (Co-60) irradiation of chest wall and regional lymphatics in patients with breast cancer along with patient age, menopausal status, body weight, observation time and adjuvant chemotherapy regimens.
MATERIALS AND METHODS: In this prospective study, 74 patients treated with post-mastectomy adjuvant radiotherapy (RT) and TAM and 37 patients treated with RT were evaluated by axial computerized tomography (CT). CT was first performed before initiation of radiotherapy and TAM treatment. A total of 824 thorax CT sections were evaluated by a radiologist blindly. Comparison of pre-treatment and post-treatment CT sections was used to monitor the development of pulmonary fibrosis.
RESULTS: Pulmonary fibrosis developed in 26 of 74 patients who were treated with RT and TAM combination. It was found in five of 37 women treated only with RT. The difference was statistically significant (P<0.01). The median time for the development of pulmonary fibrosis was 8 months in TAM-treated patients whereas it was 10 months in non-TAM-treated patients. Among 111 patients who participated in that study, 65 were in the post-menopausal state and 46 in pre-menopausal state. In the multivariate analysis, the independent prognostic factors were age (P=0.010) and menopausal status (P=0.019). Advanced age and post-menopausal status predisposed to pulmonary fibrosis. The time interval in the development of lung fibrosis and body weight did not significantly influence the results. The time interval which is one independent prognostic factor was found to be associated with lung fibrosis under only-RT group in multivariate analysis (P<0.01).
CONCLUSION: TAM treatment during post-mastectomy RT in breast cancer patients significantly increases the risk of the development of lung fibrosis along with the patient age and menopausal status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12242127     DOI: 10.1016/s0167-8140(02)00136-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  Antifibrotic effect of tamoxifen in a model of progressive renal disease.

Authors:  Humberto Dellê; José Roberto C Rocha; Rita C Cavaglieri; José Mauro Vieira; Denise M A C Malheiros; Irene L Noronha
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

2.  Use of helical tomotherapy in locally advanced and/or metastatic breast cancer for locoregional treatment.

Authors:  Laura Thery; Alexandre Arsene-Henry; Susan Carroll; Dominique Peurien; Louis Bazire; Magalie Robilliard; Alain Fourquet; Youlia M Kirova
Journal:  Br J Radiol       Date:  2018-02-05       Impact factor: 3.039

3.  Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan.

Authors:  Takaaki Konishi; Michimasa Fujiogi; Nobuaki Michihata; Ryosuke Kumazawa; Hiroyuki Ohbe; Hiroki Matsui; Kiyohide Fushimi; Mami Ogita; Masahiko Tanabe; Yasuyuki Seto; Hideo Yasunaga
Journal:  Breast Cancer       Date:  2022-02-26       Impact factor: 4.239

4.  Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy.

Authors:  Pauline T Truong; Ivo A Olivotto; Timothy J Whelan; Mark Levine
Journal:  CMAJ       Date:  2004-04-13       Impact factor: 8.262

5.  Breast pseudotumoral radionecrosis as a late radiation-induced injury: a case report.

Authors:  Holger Gerullis; Christoph Johann Heuck; Paul Schneider
Journal:  J Med Case Rep       Date:  2009-10-08

6.  Effects of hormonotherapy administered after concurrent radiotherapy and Trastuzumab on pulmonary fibrosis.

Authors:  Y Benderli Cihan; K Deniz; H Mutlu; B Kaplan
Journal:  Hippokratia       Date:  2013-07       Impact factor: 0.471

7.  Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.

Authors:  Guler Yavas; Cagdas Yavas; Hilal Acar; Hatice Toy; Deniz Yuce; Ozlem Ata
Journal:  Support Care Cancer       Date:  2012-09-01       Impact factor: 3.603

8.  Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma.

Authors:  Robin Cornelissen; Suresh Senan; Imogeen E Antonisse; Hauw Liem; Youke K Y Tan; Arjan Rudolphus; Joachim G J V Aerts
Journal:  Radiat Oncol       Date:  2007-01-03       Impact factor: 3.481

9.  Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients.

Authors:  D Azria; S Gourgou; W J Sozzi; A Zouhair; R O Mirimanoff; A Kramar; C Lemanski; J B Dubois; G Romieu; A Pelegrin; M Ozsahin
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

10.  Analysis of predictive factors for lung injury after forward-planned intensity-modulated radiotherapy in whole breast irradiation.

Authors:  Haeyoung Kim; Hoonsik Bae; Me-Yeon Lee; Kwang-Ho Cheong; Kyoung Ju Kim; Taejin Han; Sei-Kwon Kang; Soah Park; Taejin Hwang; Jai-Woong Yoon; Lee Su Kim
Journal:  J Breast Cancer       Date:  2014-03-28       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.